These new therapeutic options should be of interest in myeloid malignancies, notably MPNs, a group of diseases withchronic inflammation wherevery high HGF levels are frequent [44,45,46,47,48,49,50]. The gene discussed is HGF; the disease is myeloid neoplasm.